Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 + Nivolumab vs Sunitinib in Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 25
01
Overview
A Phase 3 trial of zanzalintinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Exelixis, Inc.. Started Jan 2023; status: active, not recruiting.
02
Drugs
zanzalintinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT05678673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678673.